Overall, our data show that tumor cell autonomous changes in STAT6 result in microenvironmental changes, and we believe further investigation could have an impact on informing standard of care for rrDLBCL patients, and potentially other B-cell malignancies identified with STAT6 mutations [10, 13, 14], by identifying novel therapeutic susceptibilities. Here, STAT6 is linked to neoplasm.